6. パーキンソン病 Parkinson disease Clinical trials / Disease details


臨床試験数 : 2,298 薬物数 : 2,218 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202

  
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04643327
(ClinicalTrials.gov)
February 9, 202118/11/2020Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's DiseaseDouble-blind Randomised-controlled Within-subject Crossover Trial to Determine Levetiracetam Efficacy for Memory Impairment in Parkinson's Disease: A Proof-of-concept StudyParkinson Disease;Mild Cognitive Impairment;Memory ImpairmentDrug: Levetiracetam;Drug: PlaceboThe University of QueenslandQueensland University of Technology;Johns Hopkins University;Cleveland Clinic Lou Ruvo Center for Brain Health;Royal Brisbane and Women's HospitalRecruitingN/AN/AAll28Phase 2Australia
2NCT00584025
(ClinicalTrials.gov)
December 200721/12/2007Keppra IV for the Treatment of Motor Fluctuations in Parkinson's DiseaseParkinson's DiseaseDrug: levetiracetam;Drug: PlaceboUniversity of South FloridaNULLWithdrawn30 Years80 YearsAll0Phase 4United States
3NCT00291733
(ClinicalTrials.gov)
May 200614/2/2006Levetiracetam Administration for the Management of Levodopa-Induced Dyskinesias in Parkinson's DiseaseLevetiracetam Administration for the Management of Levodopa-Induced Dyskinesias in Parkinson's Disease: A Double-Blind,Placebo-Controlled, Crossover TrialLevodopa Induced DyskinesiaDrug: Levetiracetam;Drug: Placebo1st Hospital of Social Security ServicesUCB PharmaActive, not recruiting30 Years80 YearsBoth50Phase 2Greece
4NCT00307450
(ClinicalTrials.gov)
March 200627/3/2006Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's DiseaseEfficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's Disease (LeLeDys Study) - A Multicenter, Randomized, Stratified, Double-blinded, Placebo-controlled Phase IV StudyParkinson's DiseaseDrug: LevetiracetamTechnische Universität DresdenUCB GmbH, Huettenstrasse 205, 50170 Kerpen, GermanyCompleted30 Years80 YearsBoth34Phase 4Germany
5NCT00076674
(ClinicalTrials.gov)
January 200428/1/2004Levetiracetam Treatment of L-dopa Induced DyskinesiasLevetiracetam Treatment of L-dopa Induced DyskinesiasDyskinesias;Parkinson DiseaseDrug: Intravenous LevodopaNational Institute of Neurological Disorders and Stroke (NINDS)NULLCompletedN/AN/ABoth40Phase 2United States
6NCT00160576
(ClinicalTrials.gov)
July 20038/9/2005Levetiracetam Treatment in Adult Subjects With Parkinson's Disease Experiencing Troublesome DyskinesiasA Therapeutic Exploratory, Single Arm, Multicenter Trial to Evaluate the Efficacy and Safety of Levetiracetam up to 4000 mg/Day (500mg Oral Tablets) on Levodopa Induced Dyskinesias in Adults With Idiopathic Parkinson's DiseaseIdiopathic Parkinson DiseaseDrug: LevetiracetamUCB PharmaNULLCompleted30 YearsN/ABoth30Phase 2NULL